Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every funding round, exec hire, M&A move, contract, and sentiment shift on Tune Therapeutics — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Tune Therapeutics raised over $175M in Series B financing led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation to advance its epigenome editing programs.
PRIVATEJan 13, 2025•over 1 year ago
Amount Raised
$175 Million
Round Type
series b
Investors
Hevolution FoundationRegeneron VenturesYosemiteNew Enterprise Associates
Description
Tune Therapeutics has completed over $175M in Series B financing, which will accelerate the development of its existing pipeline and support new gene, cell, and regenerative therapy programs. The funding is aimed at advancing their clinical-stage drug for chronic Hepatitis B and other epigenetic therapies.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech
Watching Tune Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.
See plans